Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Learning about the side effects of chemotherapy in older patients may help doctors plan better ways to treat cancer.
Stage I Ovarian Epithelial Cancer
Stage I Primary Peritoneal Cavity Cancer
Stage IA Fallopian Tube Cancer
Stage IB Fallopian Tube Cancer
Stage IC Fallopian Tube Cancer
Stage II Ovarian Epithelial Cancer
Stage II Primary Peritoneal Cavity Cancer
Stage IIA Fallopian Tube Cancer
Stage IIB Fallopian Tube Cancer
Stage IIC Fallopian Tube Cancer
Stage III Ovarian Epithelial Cancer
Stage III Primary Peritoneal Cavity Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIB Fallopian Tube Cancer
Stage IIIC Fallopian Tube Cancer
Stage IV Fallopian Tube Cancer
Stage IV Ovarian Epithelial Cancer
Stage IV Primary Peritoneal Cavity Cancer
Other: pharmacological study
Other: questionnaire administration
Procedure: assessment of therapy complications
Other: quality-of-life assessment
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer|
- Tolerance to study treatment, defined as completing four cycles of study treatment, without dose reductions or treatment delays of over seven days [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]Will be modeled with logistic regression using baseline IADL scores as a covariate. Exploratory analysis will evaluate baseline IADL scores adjusting for covariates such as: Charlson scale, nutritional status, or age.
- Percent of women, who are 70 years or older, able to complete at least 4 cycles of treatment regardless of dose reduction and delays [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]While this percentage will be estimated for each study regimen separately, the targeted sample size will limit the width of the 95%-confidence interval for the marginal percentage so that it is no larger than 0.15.
- Changes in quality-of-life measured by FACT-O, FACT/GOG-Ntx-4 subscale, IADL, and ADL [ Time Frame: Baseline to up to 6 weeks after completion of course 4 ] [ Designated as safety issue: No ]The changes in FACT-O, FACT/GOG-Ntx-4 subscale, IADL, and ADL will be summarized descriptively as the differences of scores between pre and post chemotherapy. Assuming 80% of patients complete the assessment at the completion of chemotherapy, then a sample of 148 patients will provide 90% power to detect 5 unit changes in FACT-O, 0.5 unit change in FACT/GOG-Ntx subscale score, 1 unit change in IADL or ADL score using paired t-test at significant level of 0.05.
- Changes in comorbidity index measured by the Charlson scale [ Time Frame: Baseline to up to 6 weeks after completion of course 4 ] [ Designated as safety issue: No ]
- Changes in nutritional status measured by weight [ Time Frame: Baseline to up to 6 weeks after completion of course 4 ] [ Designated as safety issue: No ]The changes in weight will be summarized descriptively as the differences of scores between pre and post chemotherapy. The change of nutritional status after completing chemotherapy will be examined using McNemar's test.
- Clinical response of elderly patients with ovarian, primary peritoneal cavity, or fallopian tube cancer [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
- Percent of patients reporting adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events [ Time Frame: Up to 6 weeks after course 4 ] [ Designated as safety issue: Yes ]The probability of an adverse event will be estimated as the percent of patients reporting an adverse event out of all patients beginning treatment.
- Pharmacokinetic parameters including paclitaxel AUC, carboplatin AUC, paclitaxel total body clearance, and time that plasma paclitaxel concentration remains above threshold 0.05 uM/L [ Time Frame: Pre-dose, 1, 6, and 24 hours ] [ Designated as safety issue: No ]The observed pharmacokinetics of paclitaxel and carboplatin will be compared with published pharmacokinetic measures of paclitaxel and carboplatin in a descriptive fashion. No formal statistical testing will be performed for the comparisons.
|Study Start Date:||August 2011|
|Estimated Primary Completion Date:||December 2019 (Final data collection date for primary outcome measure)|
Observational (quality of life questionnaire)
Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.
Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed.
Other: pharmacological study
Other Name: pharmacological studiesOther: questionnaire administration
Ancillary studiesProcedure: assessment of therapy complications
Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessmentsOther: quality-of-life assessment
Other Name: quality of life assessmentDrug: carboplatin
Other Names:Drug: paclitaxel
Other Names:Biological: filgrastim
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01366183
Show 363 Study Locations
|Principal Investigator:||Vivian von Gruenigen||Gynecologic Oncology Group|